Literature DB >> 10798066

Evaluation and treatment of chronic renal failure.

A Moudgil1, A Bagga.   

Abstract

Chronic renal failure (CRF) is the irreversible deterioration of renal function that gradually progresses to end stage renal disease (ESRD). The chief causes of CRF include obstructive uropathy, primary glomerular diseases, reflux nephropathy and hypoplastic or dysplastic kidneys. Progressive hyperperfusion and hyperfiltration causes increasing glomerular injury and further renal damage. Symptoms of CRF are usually seen when GFR is between 10-25% of normal. Children with severe CRF often suffer from failure to thrive, growth retardation, acidosis, anemia and renal osteodystrophy. Management of CRF aims at retarding progression of renal damage and treatment of complications related to renal dysfunction. Measures suggested to retard progression include protein restriction, strict control of hypertension, use of angiotensin converting enzyme inhibitors and control of hyperlipidemia. Appropriate amounts of protein and calories are recommended to prevent growth failure. Nutritional supplements are often required. The availability of recombinant erythropoietin, calcitriol and human growth hormone has significantly improved the management of these patients. Once ESRD supervenes, renal replacement therapy in the form of chronic peritoneal or hemodialysis and transplantation is necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10798066     DOI: 10.1007/bf02761215

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  29 in total

Review 1.  Measurement of renal function in chronic renal disease.

Authors:  A S Levey
Journal:  Kidney Int       Date:  1990-07       Impact factor: 10.612

Review 2.  Erythropoietin.

Authors:  A J Erslev
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience--a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study.

Authors:  M Mentser; T J Breen; E K Sullivan; R N Fine
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

4.  Purification and analysis of plasmatic components of middle molecular weight in patients with uremic syndrome.

Authors:  M C Martín Mateo; O L Cuevas Lobato; J Bustamante
Journal:  Nephron       Date:  1995       Impact factor: 2.847

Review 5.  Disorders of aldosterone biosynthesis and action.

Authors:  P C White
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

Review 6.  Hypertension and accelerated atherosclerosis in endstage renal disease.

Authors:  K Huysmans; R L Lins; R Daelemans; P Zachée; M E De Broe
Journal:  J Nephrol       Date:  1998 Jul-Aug       Impact factor: 3.902

7.  Lipids and apolipoproteins change during the progression of chronic renal failure.

Authors:  F Bergesio; G Monzani; R Ciuti; A Serruto; A Benucci; V Frizzi; M Salvadori
Journal:  Clin Nephrol       Date:  1992-11       Impact factor: 0.975

8.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

Review 9.  Hypertension in renal failure.

Authors:  R R Townsend; M Cirigliano
Journal:  Dis Mon       Date:  1998-06       Impact factor: 3.800

Review 10.  The role of the parathyroid glands in the uremic syndrome.

Authors:  E Ritz; A Stefanski; M Rambausek
Journal:  Am J Kidney Dis       Date:  1995-11       Impact factor: 8.860

View more
  1 in total

1.  Effectiveness of Comprehensive Nursing in Hemodialysis of Patients with Chronic Renal Failure and the Impact on Their Quality of Life.

Authors:  Quan Wen; Shuang Yao; Bingnan Yao
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.